Suppliers and packagers for kyprolis

kyprolis

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714	NDA	Onyx Pharmaceuticals, Inc.	76075-101-01	1 VIAL, SINGLE-USE in 1 CARTON (76075-101-01) / 30 mL in 1 VIAL, SINGLE-USE	2012-07-20
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714	NDA	Onyx Pharmaceuticals, Inc.	76075-101-21	1 VIAL, SINGLE-USE in 1 CARTON (76075-101-21) / 30 mL in 1 VIAL, SINGLE-USE	2012-07-20
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714	NDA	Onyx Pharmaceuticals, Inc.	76075-102-01	1 VIAL, SINGLE-DOSE in 1 CARTON (76075-102-01) / 15 mL in 1 VIAL, SINGLE-DOSE	2016-07-15
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714	NDA	Onyx Pharmaceuticals, Inc.	76075-102-21	1 VIAL, SINGLE-DOSE in 1 CARTON (76075-102-21) / 15 mL in 1 VIAL, SINGLE-DOSE	2016-07-15
Onyx Pharms Amgen	KYPROLIS	carfilzomib	POWDER;INTRAVENOUS	202714	NDA	Onyx Pharmaceuticals, Inc.	76075-103-01	1 VIAL, SINGLE-DOSE in 1 CARTON (76075-103-01) / 10 mL in 1 VIAL, SINGLE-DOSE	2018-05-23

Kyprolis Supplier Landscape Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for carfilzomib (Kyprolis), a proteasome inhibitor used in the treatment of multiple myeloma. The analysis focuses on key active pharmaceutical ingredient (API) manufacturers, excipient suppliers, and contract manufacturing organizations (CMOs) integral to Kyprolis production. Understanding these components is critical for assessing supply chain resilience, potential risks, and opportunities for market participants.

Who Manufactures Carfilzomib API?

The primary active pharmaceutical ingredient (API) for Kyprolis is carfilzomib. Production of this complex molecule involves specialized chemical synthesis. Key API manufacturers identified include:

• Lonza Group AG: A significant player in contract development and manufacturing for the pharmaceutical industry. Lonza has established capabilities in complex small molecule synthesis and has been a reported manufacturer or supplier of carfilzomib API. Its facilities, particularly in Visp, Switzerland, are known for handling high-potency APIs. Lonza's role often involves process development, scale-up, and commercial manufacturing.
• Amgen Inc. (through its subsidiary Onyx Pharmaceuticals): Onyx Pharmaceuticals, acquired by Amgen, developed and originally commercialized Kyprolis. While Amgen typically has internal manufacturing capabilities, it also leverages external partners for API production to ensure supply security and cost-effectiveness. Specific third-party API suppliers for Amgen/Onyx beyond Lonza are not publicly detailed in regulatory filings but are likely within Amgen's contracted network.
• Emerging API Manufacturers: The genericization landscape for high-value oncology drugs often stimulates the entry of specialized API manufacturers, particularly in Asia. Companies in India and China with demonstrated expertise in peptide synthesis and proteasome inhibitor manufacturing are likely developing or producing carfilzomib API for the generic market. However, these entities are not always disclosed until they file for regulatory approval.

Carfilzomib is a tetrapeptide epoxyketone. Its synthesis is complex, requiring multiple chiral centers and specific functional groups. The process typically involves several chemical steps, including peptide coupling, epoxidation, and protection/deprotection strategies. Ensuring high purity and stereochemical integrity is paramount.

What Excipients Are Used in Kyprolis Formulations?

Kyprolis is administered intravenously and typically supplied as a lyophilized powder for reconstitution. The formulation requires specific excipients to ensure stability, solubility, and ease of administration. Key excipients include:

• Bulking Agents: These are essential for creating a stable lyophilized cake structure.
  • Mannitol: A common cryoprotectant and bulking agent in lyophilized formulations. It helps to prevent the collapse of the product during the freeze-drying process and provides good cake formation.
  • Sucrose: Another widely used disaccharide that functions as a cryoprotectant and bulking agent. It is often used in combination with other agents to optimize lyophilization cycles.
• Buffering Agents: To maintain the pH of the reconstituted solution within a stable range.
  • Citric Acid/Sodium Citrate: A common buffer system that can be adjusted to achieve the desired pH for carfilzomib. The pH is critical for the stability of the epoxyketone moiety.
• pH Adjusters:
  • Sodium Hydroxide (NaOH): Used to adjust the pH during manufacturing.
  • Hydrochloric Acid (HCl): Used to adjust the pH during manufacturing.
• Vehicle for Reconstitution:
  • Sterile Water for Injection (SWFI): The standard diluent for reconstituting lyophilized injectable drugs.

Excipient Suppliers: The suppliers of these pharmaceutical-grade excipients are typically large, global chemical companies that specialize in high-purity ingredients meeting pharmacopeial standards (e.g., USP, EP, JP). Examples of major excipient manufacturers include:

• Roquette Frères: A global leader in plant-based ingredients, providing pharmaceutical excipients like mannitol and sucrose.
• Ashland Inc.: Offers a broad portfolio of excipients, including binders, disintegrants, and coatings, and also supplies buffering agents.
• BASF SE: A major chemical producer with a significant pharmaceutical excipients division.
• Merck KGaA (EMD Millipore): Supplies high-purity chemicals and buffers for pharmaceutical manufacturing.

The selection of excipients and their suppliers is subject to stringent quality control and regulatory oversight. Changes in excipient suppliers or the excipients themselves can necessitate revalidation of the drug product formulation and manufacturing process.

What Contract Manufacturing Organizations (CMOs) Are Involved?

The manufacturing of finished dosage forms for injectable drugs like Kyprolis, especially lyophilized products, often involves specialized contract manufacturing organizations (CMOs). These CMOs possess the aseptic processing capabilities, lyophilization expertise, and regulatory compliance required for such complex products.

• Lonza Group AG: As mentioned, Lonza also provides drug product manufacturing services. This includes formulation development, lyophilization, aseptic filling, and packaging for both clinical trial materials and commercial supply. Their integrated services, from API to finished product, can be a significant advantage for drug developers.
• Catalent Pharma Solutions: A leading global provider of drug delivery technologies and manufacturing solutions. Catalent has extensive experience in lyophilization and aseptic filling of injectable products. They operate numerous facilities globally, equipped to handle complex sterile drug manufacturing.
• Thermo Fisher Scientific (Patheon brand): Through its Patheon division, Thermo Fisher is a major provider of pharmaceutical contract manufacturing services. They offer comprehensive capabilities including sterile injectables manufacturing and lyophilization, serving many of the world's leading pharmaceutical companies.
• WuXi AppTec: A prominent China-based CRO/CDMO offering integrated services across the drug discovery and development spectrum. WuXi AppTec has been expanding its capabilities in sterile injectables and lyophilization, becoming a significant player in the global outsourcing market.

These CMOs are critical partners for Amgen/Onyx and potentially for future generic manufacturers. Their role is to scale up production efficiently while adhering to Good Manufacturing Practices (GMP) and ensuring the quality and sterility of the final drug product. The selection of a CMO is based on technical capabilities, regulatory track record, capacity, and cost.

What Are the Regulatory Considerations for Kyprolis Supply?

The supply chain for Kyprolis is heavily regulated by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). Key regulatory considerations include:

• API Master Files (APIMFs) or Drug Master Files (DMFs): API manufacturers must maintain detailed documentation about their manufacturing process, quality control, and stability data. This information is submitted to regulatory authorities in DMFs, which are then referenced by drug product applicants.
• Good Manufacturing Practices (GMP): All manufacturing sites involved in the production of Kyprolis API and finished drug product must comply with current GMP standards. Regular inspections by regulatory agencies ensure compliance.
• Supply Chain Transparency and Traceability: Regulatory bodies are increasingly focused on supply chain transparency to identify and mitigate risks. This includes understanding the origin of all critical raw materials and intermediates.
• Change Control: Any changes to the manufacturing process, suppliers, or formulation require thorough evaluation and, often, regulatory submission and approval. This is particularly stringent for the API and sterile drug product.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, such as ICH Q7 (GMP for APIs) and ICH Q10 (Pharmaceutical Quality System), provide a framework for global quality standards.
• Post-Approval Supplements: For any modifications to the approved manufacturing process, packaging, or site, the marketing authorization holder must submit supplements to the regulatory agencies.

The complexity of carfilzomib synthesis and the injectable lyophilized dosage form mean that regulatory scrutiny is intense, impacting the timelines and costs associated with bringing new suppliers or manufacturing sites online.

What Are the Supply Chain Risks and Opportunities?

Risks:

• API Manufacturing Complexity: The multi-step synthesis of carfilzomib, with its sensitive epoxyketone functionality, makes it susceptible to degradation and challenging to scale up consistently. Disruptions at a single key API supplier could have significant downstream effects.
• Geopolitical Factors and Raw Material Sourcing: Key starting materials for carfilzomib synthesis may originate from regions prone to geopolitical instability or supply chain disruptions.
• Lyophilization Expertise: Aseptic lyophilization requires specialized equipment and highly controlled environmental conditions. Limited capacity or technical issues at CMOs can lead to backorders.
• Regulatory Hurdles for New Suppliers: Qualifying new API manufacturers or CMOs is a lengthy and expensive process involving extensive validation and regulatory submissions, slowing down market entry for generics or alternative suppliers.
• Intellectual Property (IP) Landscape: While the originator's patents are a primary barrier, challenges in challenging or navigating these can delay generic competition and affect overall supply dynamics.

Opportunities:

• Emergence of Generic Competition: As key patents expire, the entry of generic carfilzomib will likely increase the number of API manufacturers and CMOs involved, potentially leading to greater supply diversity and price competition.
• Supply Chain Diversification: Pharmaceutical companies, including Amgen, are increasingly looking to diversify their supplier base to mitigate risks. This creates opportunities for qualified secondary or tertiary suppliers of API and excipients.
• Process Innovation: Opportunities exist for manufacturers to develop more efficient or cost-effective synthesis routes for carfilzomib API, potentially offering competitive advantages.
• Regional Manufacturing Expansion: Growing demand may drive investment in expanding manufacturing capacity for sterile injectables and API production in various global regions.
• Strategic Partnerships: Collaboration between API manufacturers, CMOs, and marketing authorization holders can optimize production, reduce lead times, and ensure a stable supply.

The market for Kyprolis supply is dynamic, influenced by patent expiry, regulatory changes, and evolving global manufacturing capabilities.

Key Takeaways

• Carfilzomib API production is concentrated among specialized chemical manufacturers, with Lonza Group and Amgen (via Onyx Pharmaceuticals) being key players. Generic entrants are expected to expand this landscape.
• The formulation of Kyprolis as a lyophilized product necessitates specific excipients like mannitol and sucrose, supplied by large pharmaceutical ingredient manufacturers.
• Contract Manufacturing Organizations (CMOs) with expertise in aseptic lyophilization, such as Lonza, Catalent, and Thermo Fisher Scientific, are critical for producing the finished drug product.
• The supply chain is subject to extensive regulatory oversight (FDA, EMA), requiring adherence to GMP and detailed documentation through DMFs.
• Supply chain risks include manufacturing complexity, geopolitical factors, and regulatory hurdles, while opportunities lie in generic competition, supply chain diversification, and process innovation.

Frequently Asked Questions

1. How does the complexity of carfilzomib synthesis impact supplier selection?

The multi-step synthesis and the presence of a sensitive epoxyketone moiety in carfilzomib require API manufacturers with advanced capabilities in complex organic synthesis, peptide chemistry, and chiral purity control. Suppliers must demonstrate robust process validation and consistent quality assurance to meet stringent pharmaceutical standards.

2. What are the primary challenges in ensuring a consistent supply of lyophilized Kyprolis?

Ensuring a consistent supply of lyophilized Kyprolis involves overcoming challenges in aseptic processing, precise control of lyophilization cycles, and maintaining the stability of the drug product under various storage conditions. CMOs must possess specialized lyophilization equipment and adhere to strict environmental controls to prevent microbial contamination and ensure product efficacy.

3. How do regulatory filings like Drug Master Files (DMFs) affect the qualification of new Kyprolis suppliers?

DMFs submitted by API manufacturers provide detailed proprietary information about the manufacturing process, controls, and stability of the API to regulatory authorities. For a new supplier to be qualified for use in Kyprolis production, their DMF must be accepted and reviewed by the relevant regulatory agencies. This review process can be time-consuming and requires the supplier to have comprehensive and compliant documentation in place.

4. What is the typical lead time for a company to become a qualified supplier of carfilzomib API or finished drug product?

The lead time for qualifying a new supplier for carfilzomib API or its finished drug product typically ranges from 18 to 36 months. This period accounts for process development and validation, analytical method validation, stability studies, regulatory dossier preparation and submission, and successful site audits by regulatory authorities and the marketing authorization holder.

5. How might the introduction of biosimil versions of Kyprolis impact its supply chain?

As Kyprolis is a small molecule drug, the term "biosimilar" is not applicable. However, the introduction of generic versions of carfilzomib is the relevant parallel. Generic competition will likely lead to increased demand for carfilzomib API from multiple manufacturers and a broader network of CMOs for finished product manufacturing. This could result in greater price competition and potentially more diversified sourcing options for healthcare systems.

---

Citations

[1] Lonza Group AG. (n.d.). Small Molecules. Retrieved from https://www.lonza.com/ [2] Amgen Inc. (n.d.). Our Products. Retrieved from https://www.amgen.com/ [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/ [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/ [5] Catalent Pharma Solutions. (n.d.). Injectables. Retrieved from https://www.catalent.com/ [6] Thermo Fisher Scientific. (n.d.). Contract Development and Manufacturing Services. Retrieved from https://www.thermofisher.com/ [7] WuXi AppTec. (n.d.). Small Molecule Drug Substance Manufacturing. Retrieved from https://www.wuxiapptec.com/ [8] Roquette Frères. (n.d.). Pharmaceutical Excipients. Retrieved from https://www.roquette.com/